Financial Performance - IN8bio reported a net loss of 6.2million,or0.08 per share, for Q4 2024, compared to a net loss of 7.6million,or0.22 per share, in Q4 2023[18]. - Net loss for the year ended December 31, 2024, was 30,437million,comparedtoanetlossof30,007 million in 2023, reflecting a 1.4% increase in losses[24]. - Net loss per share improved to (0.57)in2024from(1.00) in 2023, showing a significant reduction in loss per share[24]. Cash Position and Funding - The company maintained a cash position of 11.1millionasofDecember31,2024,downfrom21.3 million as of December 31, 2023[18]. - The company raised approximately 16.6millioningrossproceedsthroughequityofferingsfrom2024toFebruary2025,extendingitscashrunwayintoMarch2026[11].−ThetotalassetsofIN8biodecreasedto20.9 million as of December 31, 2024, from 33.7millionasofDecember31,2023[22].−Thecompanyreportedasignificantincreaseinadditionalpaid−incapitalto136.1 million as of December 31, 2024, compared to 116.2 million in the prior year[22]. Research and Development - R&D expenses for Q4 2024 were 3.6 million, a decrease from 4.5 million in Q4 2023, while total R&D expenses for the year were 17.0 million, slightly up from 16.8millionintheprioryear[14].−Researchanddevelopmentexpenseswere16,962 million in 2024, slightly up from 16,827millionin2023,indicatingafocusoninnovation[24].−IN8bio′sINB−100programdemonstrateda10030,667 million, an increase from $30,337 million in 2023, representing a 1.1% increase[24]. - The weighted-average number of shares used in computing net loss per share increased to 53,547,030 in 2024 from 29,864,932 in 2023, indicating potential dilution[24].
